Doublet Therapy Ups Survival in Metastatic Prostate Cancer

The use of doublet therapy has increased survival by 6 months, on average, in men with de novo metastatic castration-sensitive prostate cancer, according to Swedish registry data.
Medscape Medical News

source https://www.medscape.com/viewarticle/997343?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost